Lipocine Inc. — 2015 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2015. This is an annual filing, not a standalone fourth-quarter report; the financial comparisons are for full-year 2015 versus 2014.
Business context
Lipocine is a pre-commercial specialty pharmaceutical company developing oral drug-delivery products for men’s and women’s health. Its lead candidate, LPCN 1021, is an oral, twice-daily testosterone replacement therapy (TRT); the FDA accepted its NDA in October 2015 and set a June 28, 2016 PDUFA goal date. LPCN 1111, a planned once-daily TRT, was in Phase 2b, and LPCN 1107, an oral candidate for prevention of recurrent preterm birth, was in early clinical development.
Financial results and liquidity
| Metric | 2015 | 2014 |
|---|---|---|
| Product sales | None | None |
| Research and development expense | $12.58 million | $15.48 million |
| General and administrative expense | $5.80 million | $5.00 million |
| Operating loss | $18.38 million | $20.48 million |
| Net loss | $18.21 million | $20.37 million |
| Basic and diluted loss per share | $1.11 | $1.60 |
| Cash used in operating activities | $15.36 million | $17.30 million |
The filing reports $44.8 million of cash, cash equivalents and marketable securities at December 31, 2015, versus $27.7 million at year-end 2014. This comprised $20.0 million cash and equivalents and $24.8 million of marketable securities at 2015 year-end. Current liabilities were $3.39 million, total liabilities were $3.39 million, and the balance sheet showed no debt. The company reported total assets of $45.4 million and stockholders’ equity of $42.0 million.
Cash from financing was $32.7 million in 2015, principally reflecting a common-stock offering that generated $32.4 million net proceeds. The offering issued 5,347,500 shares. The company’s accumulated deficit was $86.4 million. It reported no off-balance-sheet arrangements.
Material changes versus 2014
- Net loss narrowed by approximately $2.2 million, while operating loss narrowed by approximately $2.1 million.
- R&D expense declined by $2.9 million, primarily because LPCN 1021 Phase 3 trial costs fell after trial completion; this was partly offset by a $2.3 million NDA filing fee.
- G&A expense increased by $0.8 million, mainly due to market research and pre-commercialization activity for LPCN 1021.
- Cash and investments increased overall, supported by the April 2015 equity financing, although cash and cash equivalents alone declined as funds were placed in marketable securities and used in operations.
- Weighted-average shares outstanding increased to 16.47 million from 12.77 million, reflecting equity issuance; loss per share improved to $1.11 from $1.60.
Outlook, risks and contingencies
- Management said existing capital resources were expected to fund projected operating requirements for at least the next 12 months, but noted that additional capital may be needed for longer-term development and commercialization. There was no credit facility or committed capital source.
- Management expected about $3.4 million of additional LPCN 1021 costs related to FDA review responses and launch-supply manufacturing, with actual costs and timing subject to uncertainty.
- Key milestones included the LPCN 1021 FDA decision target of June 28, 2016; anticipated LPCN 1111 Phase 2b results in the second quarter of 2016; and a planned FDA end-of-Phase 2 meeting for LPCN 1107 in the second quarter of 2016. These were expectations, not guarantees.
- TRT class risks include FDA restrictions on eligible patients, safety warnings and possible post-approval cardiovascular studies. The company did not expect such a study to be required before LPCN 1021 approval based on its FDA meeting, but acknowledged possible post-approval obligations.
- Clarus Therapeutics sued in November 2015, alleging LPCN 1021 would infringe its U.S. Patent No. 8,828,428; Lipocine filed a motion to dismiss in January 2016. Separately, a patent interference proceeding was declared, with Lipocine designated the senior party. The filing states no litigation contingency was accrued because management did not consider any contingency probable and estimable.
- The company depends on third parties for testosterone undecanoate supply and LPCN 1021 manufacturing. A March 2016 agreement with Encap covered commercial supply and included annual minimum-purchase commitments subject to the agreement’s terms.
- LPCN 1021 carries a perpetual 1% royalty on net sales payable to Abbott, capped at $1 million in each of the first two calendar years after launch; thereafter the royalty is uncapped, subject to a 50% reduction if generic versions are introduced.
- The independent auditor issued an unqualified opinion. Management reported effective disclosure controls and internal control over financial reporting as of December 31, 2015.
Most important facts for investors to verify
- The FDA’s eventual action on LPCN 1021, any labeling or cardiovascular-study requirements, and the effect of TRT class restrictions on the addressable market.
- Whether the Clarus patent litigation and interference proceeding affect LPCN 1021’s ability to be approved, manufactured or commercialized, and the resulting legal costs.
- Whether reported liquidity remains adequate as commercialization preparations and pipeline development consume cash, and whether further financing or dilution is required.
- Commercial manufacturing readiness, supply availability and the financial implications of Encap’s purchase commitments and Abbott’s royalty.
- Whether LPCN 1111 and LPCN 1107 meet planned clinical and regulatory milestones; early-stage results do not establish later-stage efficacy, safety or approval.